$19MVenture, 12 June 2025
Private financing to expand the Phase 1/2 SIDNEY trial of EO2463 in indolent non-Hodgkin lymphoma and prepare a registrational trial.
- Amount
- $19M
- Stage
- Venture
- Announced
- 12 June 2025
- Lead
- Institute for Follicular Lymphoma Innovation
- Other investors
- SymBiosis, Seventure Partners, Lundbeckfonden BioCapital, Primo Capital, Leukemia & Lymphoma Society Therapy Acceleration Program
- Use of funds
- Private financing to expand the Phase 1/2 SIDNEY trial of EO2463 in indolent non-Hodgkin lymphoma and prepare a registrational trial.
- Checked
- Announced by the company
- Sources
- Enterome raises USD 19 million to advance its follicular lymphoma program seventure.fr
Enterome raises USD 19 million to advance its follicular lymphoma program journaldunet.com